ARC-520

yelanglms

我感觉5年内，一定有高效药物出现，乙肝的治疗会取得突破性进展！现在还没有发生肝炎的，对乙肝不用有任何担心了！

yelanglms

请大家说说把各类有前景的药物都放在一个贴里比较，这样是否好？

StephenW

Arrowhead to Present at Upcoming Conferences


PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will present at the following upcoming investor and scientific conferences.

IBC's 17th Annual TIDES Conference - San Diego, May 3-6, 2015

May 5, 4:45 p.m. PDT - Christine Wooddell, Ph.D., group leader will deliver an oral presentation titled, "A Hepatocyte-Targeted RNAi Therapeutic for Alpha-1-Antitrypsin Deficiency-Associated Liver Disease"

May 6, 12:15 p.m. PDT - David Lewis, Ph.D., chief scientific officer will deliver an oral presentation titled, "A Targeted siRNA-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection"

Deutsche Bank 40th Annual Health Care Conference - Boston, May 6-7, 2015

May 7, 2:50 p.m. EDT - Bruce Given, M.D., chief operating officer will make a corporate presentation

A live webcast of the presentation from the Deutsche Bank conference can be accessed by visiting the Events section of the company's website at http://ir.arrowheadresearch.com/events.cfm. A replay will also be archived on the website.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.

StephenW

箭头将出席即将举行的会议


加利福尼亚州帕萨迪纳 - （BUSINESS WIRE） - 箭头研究公司（纳斯达克股票代码：ARWR），一家生物制药公司开发有针对性的RNAi疗法，今天宣布，该公司将出席即将如下投资者和科学会议。

IBC的第17届年度会议潮汐 - 圣迭戈月3-6 2015年

5月5日下午4:45 PDT - 恭Wooddell，博士，组长将提供一个口头报告题为“肝细胞靶向治疗的RNAi为α-1抗胰蛋白酶缺乏，相关肝病”

5月6日，12:15 PM PDT大卫 - 路易斯，博士，首席科学官将提供口头介绍题为“有针对性的基于siRNA的用于治疗慢性乙型肝炎病毒感染的治疗”

德意志银行第40届卫生保健大会 - 波士顿，5月6-7日，2015年

5月7日，下午2:50 EDT - 布鲁斯考虑，医学博士，首席运营官将企业介绍

来自德意志银行会议演示文稿的网上直播可以通过访问该公司网站的活动部分在http://ir.arrowheadresearch.com/events.cfm访问。重播也将被封存在网站上。

关于箭头研究公司

箭头研究公司是一家生物制药公司，开发有针对性的RNAi疗法。该公司利用其专有的动态Polyconjugate™交付平台来开发基于能够有效地沉默致病基因的RNA干扰机制的靶向药物。箭头的管道包括ARC-520用于治疗慢性乙型肝炎病毒和ARC-AAT用于与α-1抗胰蛋白酶缺乏相关的肝脏疾病。

欲了解更多信息，请访问http://www.arrowheadresearch.com，或关注我们的微博@ArrowRes。要添加到该公司的电子邮件列表，并直接收到的消息，请访问http://ir.arrowheadresearch.com/alerts.cfm。

Zongguoyiren

不知道会上会不会透露点消息

StephenW

回复 Zongguoyiren 的帖子

不会. 任何新闻，无论好坏，都必须公开.

hao2014

从去年开始

参加了很多会议，慢慢也就麻木了

科学实验只能慢慢来

StephenW

Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery


PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the publication of new data on a subcutaneously administered formulation of its Dynamic Polyconjugate (DPC) delivery system. The company believes the new DPCs are highly potent and may represent a dramatic improvement in duration of activity over competing technologies. This new class of DPCs may also enable targeting of RNAi therapeutics to tissues outside of the liver. The manuscript entitled, "Protease-triggered siRNA delivery vehicles," by David B. Rozema et al, was made available online ahead of print in the Journal of Controlled Release 209 (2015) 57-66.

In the publication, Arrowhead scientists describe the development of protease-sensitive masking chemistries that are used in a class DPCs where the RNAi trigger molecule is conjugated directly to the polymer delivery vehicle. These new vehicles expand on the company's existing acid labile DPCs, where the polymer and RNAi trigger are two separate molecules and are co-injected. The protease-sensitive linkages appear to be more stable and have longer circulation times, which may allow for an increased range of targeting, and appear amenable to subcutaneous administration. The publication reports a high level of target gene knockdown and long duration of effect can be achieved after subcutaneous injection with these new DPC delivery vehicles in nonhuman primates. After a single subcutaneous injection of 0.5 mg/kg siRNA against Factor 7 (FVII), a liver expressed coagulation factor that is secreted into the bloodstream, a 99% reduction of FVII activity was observed in nonhuman primates. Further, this reduction was highly durable with maximal knockdown occurring 24 days after injection and measurable reduction in FVII activity appears to persist for up to 200 days.

"This publication speaks to the flexibility of the DPCs and the ability of our scientists to continually expand the platform to enable additional uses," said Christopher Anzalone, Ph.D., president and chief executive officer. "These data suggest that subcutaneously administered DPCs that employ the protease sensitive masking chemistries may be well suited to address chronic diseases of the liver that require long-term treatment and where long dosing intervals would be very attractive to physicians and patients."

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit

http://ir.arrowheadresearch.com/alerts.cfm.

StephenW

箭头在皮下的siRNA传递进展数据发布


加利福尼亚州帕萨迪纳 - （BUSINESS WIRE） - 箭头研究公司（纳斯达克股票代码：ARWR），一家生物制药公司开发有针对性的RNAi疗法，今天宣布的新的数据在它的动态Polyconjugate（DPC）输送系统的皮下给药制剂公布。该公司认为，新的DPC是非常有效的，可能代表活动的持续时间的显着改善竞争技术。这个新的类毛乳头细胞，也可能使RNAi疗法靶向组织中的肝外。题为“蛋白酶触发的siRNA运载工具，”由大卫B. Rozema等人的手稿，制成控释209（2015）57-66可在网上提前打印在杂志上。

在出版物中，箭头科学家描述的那些中的一类的DPC，其中所述RNAi触发分子被直接结合到聚合物输送车辆中使用蛋白酶敏感的掩蔽化学的发展。这些新的车辆扩大公司现有的酸不稳定的DPC，其中聚合物和RNAi触发器是两个独立的分子和被共同注入。蛋白酶敏感键显得更稳定，具有更长的循环时间，这可以允许靶向的增加的范围内，并且出现适合于皮下施用。该出版物报告可以皮下注射与这些新的DPC运载工具在非人灵长类动物后实现靶基因敲除和效果持续时间长的一个高的水平。单次皮下注射0.5毫克/公斤的siRNA对因子7（FVII），即分泌到血流肝脏表达凝血因子后，观察到在非人灵长类动物的减少FVII活性的99％。此外，这种减少与最大击倒发生24天注射的，可衡量的减少FVII活动后高度耐用出现持续长达200天。

“本出版物讲的毛乳头细胞的弹性和我们的科学家不断拓展平台，使更多的用途的能力，”克里斯托弗Anzalone，博士，总裁兼首席执行官说。 “这些数据表明，皮下给药雇用蛋白酶敏感掩蔽化学可以很好适于处理肝脏需要长期治疗并且其中长给药间隔将是医生和患者非常有吸引力的慢性疾病的DPC”。

关于箭头研究公司

箭头研究公司是一家生物制药公司，开发有针对性的RNAi疗法。该公司利用其专有的动态Polyconjugate™交付平台来开发基于能够有效地沉默致病基因的RNA干扰机制的靶向药物。箭头的管道包括ARC-520用于治疗慢性乙型肝炎病毒和ARC-AAT用于与α-1抗胰蛋白酶缺乏相关的肝脏疾病。

欲了解更多信息，请访问http://www.arrowheadresearch.com，或关注我们的微博@ArrowRes。要添加到该公司的电子邮件列表，并直接收到的消息，请访问：

齐欢畅2

Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the publication of new data on a subcutaneously administered formulation of its Dynamic Polyconjugate (DPC) delivery system. The company believes the new DPCs are highly potent and may represent a dramatic improvement in duration of activity over competing technologies. This new class of DPCs may also enable targeting of RNAi therapeutics to tissues outside of the liver. The manuscript entitled, "Protease-triggered siRNA delivery vehicles," by David B. Rozema et al, was made available online ahead of print in the Journal of Controlled Release 209 (2015) 57-66.

In the publication, Arrowhead scientists describe the development of protease-sensitive masking chemistries that are used in a class DPCs where the RNAi trigger molecule is conjugated directly to the polymer delivery vehicle. These new vehicles expand on the company's existing acid labile DPCs, where the polymer and RNAi trigger are two separate molecules and are co-injected. The protease-sensitive linkages appear to be more stable and have longer circulation times, which may allow for an increased range of targeting, and appear amenable to subcutaneous administration. The publication reports a high level of target gene knockdown and long duration of effect can be achieved after subcutaneous injection with these new DPC delivery vehicles in nonhuman primates. After a single subcutaneous injection of 0.5 mg/kg siRNA against Factor 7 (FVII), a liver expressed coagulation factor that is secreted into the bloodstream, a 99% reduction of FVII activity was observed in nonhuman primates. Further, this reduction was highly durable with maximal knockdown occurring 24 days after injection and measurable reduction in FVII activity appears to persist for up to 200 days.

"This publication speaks to the flexibility of the DPCs and the ability of our scientists to continually expand the platform to enable additional uses," said Christopher Anzalone, Ph.D., president and chief executive officer. "These data suggest that subcutaneously administered DPCs that employ the protease sensitive masking chemistries may be well suited to address chronic diseases of the liver that require long-term treatment and where long dosing intervals would be very attractive to physicians and patients."